Cambridge Investment Research Advisors
RGLS

Cambridge Investment Research Advisors’s Regulus Therapeutics RGLS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,400
Closed -$10K – 3255
2021
Q3 		$10K Buy
+1,400
New +$10.3K ﹤0.01% 3074

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cambridge Investment Research Advisors's RGLS Position: Q4 2021 in Review

Cambridge Investment Research Advisors sold out of Regulus Therapeutics (RGLS) in Q4 2021, closing a stake of 1,400 shares — an estimated $10K sold.

Cambridge Investment Research Advisors first reported a position in RGLS in Q3 2021 and held it in 1 quarter. The position peaked at $10K in Q3 2021. 37 funds tracked by Wall St. Rank hold RGLS as of Q4 2021.

  • Cambridge Investment Research Advisors reported no remaining Regulus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 1,400 Regulus Therapeutics shares in Q4 2021, an estimated $10K.
  • Cambridge Investment Research Advisors first reported a position in Regulus Therapeutics in Q3 2021 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Regulus Therapeutics position peaked at $10K in Q3 2021.
  • 37 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.